Roche's Divarasib Shows Positive Results in Late-Stage Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Source: NASDAQ.COM
- Clinical Trial Success: Roche's Divarasib demonstrated significant efficacy in the Krascendo 1 study for previously treated KRAS G12C non-small cell lung cancer patients, showing clinically meaningful improvements in progression-free and overall survival, potentially establishing a new standard of care.
- Market Competitive Edge: This study is the only global head-to-head trial comparing KRAS G12C inhibitors, with Divarasib showing superior treatment potential against Amgen's Lumakras and BMY's Krazati, which may enhance Roche's competitive position in the lung cancer market.
- FDA Breakthrough Therapy Designation: Divarasib received Breakthrough Therapy Designation from the FDA in 2022, which is expected to expedite its approval process, addressing the urgent treatment needs of patients with KRAS G12C mutations and filling a significant market gap.
- Strategic Collaboration Expansion: Roche entered into an exclusive licensing agreement with Nurix Therapeutics to co-develop and commercialize bexobrutideg, which is expected to provide new growth opportunities for Roche's hematology pipeline while strengthening its presence in immunology and neurology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 58.130
Low
37.00
Averages
55.86
High
68.00
Current: 58.130
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vanguard Research Bullish on U.S. Economic Outlook
- GDP Growth Forecast: Vanguard's research projects a 3% growth in U.S. GDP by 2027, which is likely to positively impact U.S. stock markets, especially with core inflation expected to drop to 2.7%, potentially boosting bond prices.
- Value Stock Investment Opportunity: The research highlights that U.S. value stocks could be a good investment choice, as these companies are positioned to benefit from AI productivity gains without incurring upfront costs for AI data centers and capital expenditures, thereby enhancing investor return potential.
- Vanguard Value Factor ETF Performance: The Vanguard U.S. Value Factor ETF (VFVA) has seen a 28.1% increase over the past year and a 12.9% gain in the first half of 2023, underscoring its significance in a diversified portfolio, particularly with holdings across financials, consumer discretionary, and healthcare sectors.
- Bond Market Outlook: The Vanguard Total Bond Market ETF (BND) has delivered an average annual return of 3.1% since its inception in 2007, despite only 0.1% over the past five years; however, if inflation and interest rates decline as projected, future bond investments could yield better returns.
See More
Vanguard Research Bullish on Value Stocks and Bonds
- Value Stock Investment Opportunity: The Vanguard U.S. Value Factor ETF has outperformed the S&P 500 index with a 28.1% annual return over the past year, and its P/E ratio of 11 indicates a significant discount compared to the S&P 500's 25, suggesting that value stocks could be a good investment choice in the coming years.
- Bond Market Outlook: Despite the Vanguard Total Bond Market ETF's average annual return of only 0.1% over the past five years, it has delivered an average annual return of 3.1% since its inception in 2007, indicating potential for long-term investment, especially as inflation and interest rates may decline.
- Diversified Portfolio: The Vanguard U.S. Value Factor ETF holds a portfolio of 649 stocks across large-cap, mid-cap, and small-cap categories, with top sector holdings including financials (23.5%) and consumer discretionary (18.5%), ensuring broad diversification and reducing sector-specific risks.
- Low Cost Advantage: The Vanguard Total Bond Market ETF features an ultra-low expense ratio of 0.03%, making it a cost-effective option in the bond ETF space, and its diversified portfolio of 11,455 bonds provides a solid yield potential, making it suitable for a long-term investor's diversified strategy.
See More
Roche's Divarasib Shows Positive Results in Late-Stage Study
- Clinical Trial Success: Roche's Divarasib demonstrated significant efficacy in the Krascendo 1 study for previously treated KRAS G12C non-small cell lung cancer patients, showing clinically meaningful improvements in progression-free and overall survival, potentially establishing a new standard of care.
- Market Competitive Edge: This study is the only global head-to-head trial comparing KRAS G12C inhibitors, with Divarasib showing superior treatment potential against Amgen's Lumakras and BMY's Krazati, which may enhance Roche's competitive position in the lung cancer market.
- FDA Breakthrough Therapy Designation: Divarasib received Breakthrough Therapy Designation from the FDA in 2022, which is expected to expedite its approval process, addressing the urgent treatment needs of patients with KRAS G12C mutations and filling a significant market gap.
- Strategic Collaboration Expansion: Roche entered into an exclusive licensing agreement with Nurix Therapeutics to co-develop and commercialize bexobrutideg, which is expected to provide new growth opportunities for Roche's hematology pipeline while strengthening its presence in immunology and neurology.
See More
Investment Choice Between Bristol Myers Squibb and Johnson & Johnson
- Financial Performance Comparison: Bristol Myers Squibb reported nearly $48.2 billion in revenue for fiscal 2025, reflecting a slight 0.2% decrease year-over-year, with a net income of approximately $7.1 billion and a net margin of 14.6%, indicating recovery from a significant loss in the previous year despite facing pricing pressures and loss of market exclusivity risks.
- Growth Potential of Johnson & Johnson: Johnson & Johnson achieved approximately $94.2 billion in revenue for fiscal 2025, marking a nearly 6% year-over-year increase, with a net income of around $26.8 billion and a net margin of 28.5%, demonstrating the effectiveness of its dual strategy in innovative medicines and MedTech in driving financial growth.
- Debt and Liquidity Analysis: Bristol Myers Squibb has a debt-to-equity ratio of 2.6, indicating high reliance on borrowed funds, while Johnson & Johnson's ratio stands at only 0.6, reflecting a more robust financial structure, with current ratios of 1.3 and 1.0 respectively, highlighting differences in short-term debt coverage capabilities.
- Legal Risks and Market Competition: Bristol Myers Squibb faces pricing pressures from the Inflation Reduction Act, while Johnson & Johnson must contend with significant litigation risks related to its talc-containing products, which could impact financial results, and is at a disadvantage in the competitive landscape against biosimilars, illustrating the distinct challenges each company faces in their market environments.
See More
Investment Choice Between Bristol Myers Squibb and Johnson & Johnson
- Financial Performance Comparison: Bristol Myers Squibb reported nearly $48.2 billion in revenue for fiscal 2025, reflecting a slight 0.2% decrease from the previous year, with a net income of approximately $7.1 billion and a net margin of 14.6%, indicating recovery after significant business shifts; in contrast, Johnson & Johnson achieved approximately $94.2 billion in revenue, up nearly 6% year-over-year, with a net income of $26.8 billion and a net margin of 28.5%, showcasing the strong growth potential of its diversified business model.
- Debt and Liquidity Analysis: Bristol Myers Squibb has a debt-to-equity ratio of about 2.6, indicating a high reliance on borrowed funds, with a current ratio of 1.3 suggesting adequate short-term debt coverage; in comparison, Johnson & Johnson's debt-to-equity ratio is only 0.6, with a current ratio of 1.0, reflecting its financial stability and lower debt risk.
- Market Competition and Risks: Bristol Myers Squibb faces pricing pressures from the Inflation Reduction Act, particularly regarding government-negotiated prices for key drugs like Eliquis, while the loss of exclusivity for Revlimid may open the market to cheaper generics; meanwhile, Johnson & Johnson must manage significant litigation risks related to its talc-containing products, which could impact financial results.
- Investment Value Assessment: Bristol Myers Squibb currently trades at a significant discount compared to Johnson & Johnson and the broader sector, and despite facing legal liabilities and market challenges, its
See More
Market Capitalization Comparison: Dell vs. Bristol Myers
- Market Cap Comparison: Dell Technologies (DELL) has a market capitalization of $134.70 billion compared to Bristol Myers Squibb (BMY) at $119.58 billion, indicating Dell's relative strength in attracting large fund investments.
- Investor Misconceptions: Many novice investors mistakenly believe that a higher stock price equates to greater company value, whereas market capitalization provides a more accurate comparison of company worth, aiding in informed investment decisions.
- Market Positioning Impact: Market cap determines a company's size tier among peers, directly influencing which mutual funds and ETFs are willing to hold the stock, particularly large-cap funds that prefer companies valued over $10 billion.
- Stock Performance: As of Tuesday's close, Dell's stock rose approximately 4%, while BMY remained flat, reflecting positive market sentiment and increased investor confidence in Dell.
See More
Vanguard Research Bullish on U.S. Economic Outlook
- GDP Growth Forecast: Vanguard's research projects a 3% growth in U.S. GDP by 2027, which is likely to positively impact U.S. stock markets, especially with core inflation expected to drop to 2.7%, potentially boosting bond prices.
- Value Stock Investment Opportunity: The research highlights that U.S. value stocks could be a good investment choice, as these companies are positioned to benefit from AI productivity gains without incurring upfront costs for AI data centers and capital expenditures, thereby enhancing investor return potential.
- Vanguard Value Factor ETF Performance: The Vanguard U.S. Value Factor ETF (VFVA) has seen a 28.1% increase over the past year and a 12.9% gain in the first half of 2023, underscoring its significance in a diversified portfolio, particularly with holdings across financials, consumer discretionary, and healthcare sectors.
- Bond Market Outlook: The Vanguard Total Bond Market ETF (BND) has delivered an average annual return of 3.1% since its inception in 2007, despite only 0.1% over the past five years; however, if inflation and interest rates decline as projected, future bond investments could yield better returns.
See More
Vanguard Research Bullish on Value Stocks and Bonds
- Value Stock Investment Opportunity: The Vanguard U.S. Value Factor ETF has outperformed the S&P 500 index with a 28.1% annual return over the past year, and its P/E ratio of 11 indicates a significant discount compared to the S&P 500's 25, suggesting that value stocks could be a good investment choice in the coming years.
- Bond Market Outlook: Despite the Vanguard Total Bond Market ETF's average annual return of only 0.1% over the past five years, it has delivered an average annual return of 3.1% since its inception in 2007, indicating potential for long-term investment, especially as inflation and interest rates may decline.
- Diversified Portfolio: The Vanguard U.S. Value Factor ETF holds a portfolio of 649 stocks across large-cap, mid-cap, and small-cap categories, with top sector holdings including financials (23.5%) and consumer discretionary (18.5%), ensuring broad diversification and reducing sector-specific risks.
- Low Cost Advantage: The Vanguard Total Bond Market ETF features an ultra-low expense ratio of 0.03%, making it a cost-effective option in the bond ETF space, and its diversified portfolio of 11,455 bonds provides a solid yield potential, making it suitable for a long-term investor's diversified strategy.
See More
Roche's Divarasib Shows Positive Results in Late-Stage Study
- Clinical Trial Success: Roche's Divarasib demonstrated significant efficacy in the Krascendo 1 study for previously treated KRAS G12C non-small cell lung cancer patients, showing clinically meaningful improvements in progression-free and overall survival, potentially establishing a new standard of care.
- Market Competitive Edge: This study is the only global head-to-head trial comparing KRAS G12C inhibitors, with Divarasib showing superior treatment potential against Amgen's Lumakras and BMY's Krazati, which may enhance Roche's competitive position in the lung cancer market.
- FDA Breakthrough Therapy Designation: Divarasib received Breakthrough Therapy Designation from the FDA in 2022, which is expected to expedite its approval process, addressing the urgent treatment needs of patients with KRAS G12C mutations and filling a significant market gap.
- Strategic Collaboration Expansion: Roche entered into an exclusive licensing agreement with Nurix Therapeutics to co-develop and commercialize bexobrutideg, which is expected to provide new growth opportunities for Roche's hematology pipeline while strengthening its presence in immunology and neurology.
See More
Investment Choice Between Bristol Myers Squibb and Johnson & Johnson
- Financial Performance Comparison: Bristol Myers Squibb reported nearly $48.2 billion in revenue for fiscal 2025, reflecting a slight 0.2% decrease year-over-year, with a net income of approximately $7.1 billion and a net margin of 14.6%, indicating recovery from a significant loss in the previous year despite facing pricing pressures and loss of market exclusivity risks.
- Growth Potential of Johnson & Johnson: Johnson & Johnson achieved approximately $94.2 billion in revenue for fiscal 2025, marking a nearly 6% year-over-year increase, with a net income of around $26.8 billion and a net margin of 28.5%, demonstrating the effectiveness of its dual strategy in innovative medicines and MedTech in driving financial growth.
- Debt and Liquidity Analysis: Bristol Myers Squibb has a debt-to-equity ratio of 2.6, indicating high reliance on borrowed funds, while Johnson & Johnson's ratio stands at only 0.6, reflecting a more robust financial structure, with current ratios of 1.3 and 1.0 respectively, highlighting differences in short-term debt coverage capabilities.
- Legal Risks and Market Competition: Bristol Myers Squibb faces pricing pressures from the Inflation Reduction Act, while Johnson & Johnson must contend with significant litigation risks related to its talc-containing products, which could impact financial results, and is at a disadvantage in the competitive landscape against biosimilars, illustrating the distinct challenges each company faces in their market environments.
See More
Investment Choice Between Bristol Myers Squibb and Johnson & Johnson
- Financial Performance Comparison: Bristol Myers Squibb reported nearly $48.2 billion in revenue for fiscal 2025, reflecting a slight 0.2% decrease from the previous year, with a net income of approximately $7.1 billion and a net margin of 14.6%, indicating recovery after significant business shifts; in contrast, Johnson & Johnson achieved approximately $94.2 billion in revenue, up nearly 6% year-over-year, with a net income of $26.8 billion and a net margin of 28.5%, showcasing the strong growth potential of its diversified business model.
- Debt and Liquidity Analysis: Bristol Myers Squibb has a debt-to-equity ratio of about 2.6, indicating a high reliance on borrowed funds, with a current ratio of 1.3 suggesting adequate short-term debt coverage; in comparison, Johnson & Johnson's debt-to-equity ratio is only 0.6, with a current ratio of 1.0, reflecting its financial stability and lower debt risk.
- Market Competition and Risks: Bristol Myers Squibb faces pricing pressures from the Inflation Reduction Act, particularly regarding government-negotiated prices for key drugs like Eliquis, while the loss of exclusivity for Revlimid may open the market to cheaper generics; meanwhile, Johnson & Johnson must manage significant litigation risks related to its talc-containing products, which could impact financial results.
- Investment Value Assessment: Bristol Myers Squibb currently trades at a significant discount compared to Johnson & Johnson and the broader sector, and despite facing legal liabilities and market challenges, its
See More
Market Capitalization Comparison: Dell vs. Bristol Myers
- Market Cap Comparison: Dell Technologies (DELL) has a market capitalization of $134.70 billion compared to Bristol Myers Squibb (BMY) at $119.58 billion, indicating Dell's relative strength in attracting large fund investments.
- Investor Misconceptions: Many novice investors mistakenly believe that a higher stock price equates to greater company value, whereas market capitalization provides a more accurate comparison of company worth, aiding in informed investment decisions.
- Market Positioning Impact: Market cap determines a company's size tier among peers, directly influencing which mutual funds and ETFs are willing to hold the stock, particularly large-cap funds that prefer companies valued over $10 billion.
- Stock Performance: As of Tuesday's close, Dell's stock rose approximately 4%, while BMY remained flat, reflecting positive market sentiment and increased investor confidence in Dell.
See More
